ArBlast arblast.jp


Public lists: Pharma Startups (4743)

ArBlast is ArBlast was established in December 2005. Using the collagen sheet obtained by processing the human amniotic membrane, it is a regenerative medicine venture that regenerates various tissues.

ArBlast is ArBlast was established in December 2005. Using the collagen sheet obtained by processing the human amniotic membrane, it is a regenerative medicine venture that regenerates various tissues.

Company (Alive / Active)

Phone: 81-78-304-5870

Fax: 81-78-304-5871

5-5-2 Minatojima-minamimachi
650-0047
Japan

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
ArBlast $0M Apr 19, 2019
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related ArBlast Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

BioMimetic Therapeutics

Franklin, Tennessee, United States
AcquiredBioMimetic Pharmaceuticals (BMTI) is a biopharmaceutical company focused on the development, commercialization and ultimate marketing of protein therapeutics for tissue and organ regeneration. The Company's lead technologies are for the healing and restoration of bone and other tissues. Its lead products are based on recombinant human platelet-derived growth factor BB (rhPDGF-BB). In March 2013, BioMimetic Therapeutics was acquired by Wright Medical Group. The valuation of BioMimetic Therapeuti...Show allLogin to see details

Ikaria

Hampton, New Jersey, United States
AcquiredIkaria is a critical care company focused on developing and commercializing therapies designed to address the significant needs of critically ill patients. The company's product, INOMAX (Inhaled Nitric Oxide) is a vasodilator which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks) neonates.Login to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Sheet-like composition Jul 19, 2006 Jul 31, 2012 Patent